These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Can risk factor modification prevent nephropathy in type 2 diabetes mellitus? Wesson DE Am J Kidney Dis; 2000 Nov; 36(5):1054-6. PubMed ID: 11054366 [No Abstract] [Full Text] [Related]
24. Chronic kidney disease. Avoiding the point of no return. Compton A Adv Nurse Pract; 2004 Jun; 12(6):75-8. PubMed ID: 15218593 [No Abstract] [Full Text] [Related]
25. Fighting diabetic kidney disease. The best defense is a good offense--take action now to prevent kidney disease. Hirsch IB Diabetes Forecast; 2002 Feb; 55(2):68-70. PubMed ID: 14959672 [No Abstract] [Full Text] [Related]
37. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. Bakris GL; Toto RD; McCullough PA J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206 [TBL] [Abstract][Full Text] [Related]
38. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes: response to Shultis et al. Varon FN Diabetes Care; 2007 Dec; 30(12):e138; author reply e139. PubMed ID: 18042747 [No Abstract] [Full Text] [Related]
39. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy. Lo MK; Lee KF; Chan NN; Leung WY; Ko GT; Chan WB; So WY; Ng MC; Ho CS; Tam JS; Lam CW; Tong PC; Chan JC Diabetes Obes Metab; 2004 May; 6(3):223-30. PubMed ID: 15056131 [TBL] [Abstract][Full Text] [Related]
40. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico. Arredondo A; Burke TA; Carides GW; Lemus E; Querol J Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]